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Introduction 
1. Childhood liver tumors 
1.1 Epidemiology 
Pediatric cancers represent the highest morbidity and mortality related with disease in 
childhood. They encompass widely known cancer types such as leukemias, lymphomas, 
brain tumors, and liver cancers. Pediatric liver tumors contain two most frequently 
occurring groups: hepatoblastoma (HB) and hepatocellular carcinoma (HCC). HB is 
known to be the most common pediatric liver tumor and represents approximately 80% of 
the liver cancers affecting children predominantly between age of 6 months and 3 years, 
while HCC is found more uncommon, which about only 0.5%–1% of childhood cancers 
are classified as HCC. Most of HB are diagnosed under 5 years of age, whereas the 
patients diagnosed at over 5 years mostly have unfavorable prognosis [1]. It has an annual 
incidence rate of approximately 1.8 diagnosed cases per million [2] and accounts for less 
than 5% of pediatric malignancies [3]. It has been reported that low birth weight (<1,500g) 
and low birth weight (1,500g-2,500g) increases the risk of HB about 20-fold and doubles 
the risk of HB, respectively [4]. In HCC, contrary to adults, there are less etiologic factors 
that can be detected in the majority of children and adolescents. However, the probability 
of having HCC in chronic hepatitis B virus (HBV) carriers represent with higher prevalence 
of HBV infection rate, which estimated to be 10%-25% [5]. HCC patients’ 3-year survival 
is under 20% with unresectable HCC treated with independent chemotherapy. 
Considering the fact that HB is the most frequent liver tumor in childhood, the following 
parts mainly focus on HB.  
 
1.2 Clinical implication  
Younger age at diagnosis is always predictive for better overall survival [6]. HBs are rarely 
composed of only one cell type, which makes their diagnosis more challenging. The tumor 
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is usually becoming large at diagnosis, and the alpha-fetoprotein (AFP) is nearly evaluated 
in all patients. This result offers the opportunity of HB be diagnosed in early stages. Recent 
research reported that partial hepatectomy after chemotherapy offers a good chance of 
survival for HB children [7]. To plan the surgery in an objective and comparable manner 
is always necessary, although it’s still difficult to decide which patients deserve immediate 
surgery, while which were not [8]. Among all the staging methods, the development of the 
system for assessing the pretreatment extent of tumor (PRETEXT) in the liver is 
mentionable here (Figure. 1), which was established for better patient diagnosis to select 
suitable treatment options [9]. It's created by the International Childhood Liver Tumor 
Strategy Group (SIOPEL group) based on characterizing the location of tumors with 
Couinaud’s system of segmentation of the liver. Although the surgical timing is mostly 
dependent on therapeutic schedule and patients’ response, the preoperative reimaging is 
always necessary. As a result, staging and treatment are a crucial part of patients’ 
management [10]. With a dreadful outcome of HB, its treatment still makes progress due 
to improved surgical techniques and better chemotherapy based on increasingly risk 
stratification. In addition, the beneficial accumulated experiences shared through 
international collaboration has led to an increased understanding. 
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.  
Figure.1 PRETEXT system staging the liver tumors. A: PRETEXT I, one section is involved and three 
adjoining sections are free. B: PRETEXT II, one or two sections are involved, but two adjoining sections are 
free. C: PRETEXT III, two or three sections are involved, and no two adjoining sections are free. D: 
PRETEXT IV, all four sections are involved. Figures are taken from Roebuck et al. [10]. 
 
2. Histopathology of HB 
The various combination of epithelial and mesenchymal cell lineages characterize a rare 
malignant blastomatous tumor, HB, which recapitulate early phases of liver ontogenesis. 
HB cell types have been differentiated from immature hepatocyte precursors, including 
epithelial, biliary, hepatocytes, mesenchymal, and mixed epithelial-mesenchymal types. 
Epithelial tumors can be breaking down into fetal, embryonal, and small cell 
undifferentiated subtypes, while the mixed epithelial-mesenchymal group can be further 
classified according to their teratoid features. But, it is still not clear to attach the tumor 
with the proportions of fetal, embryonal and small-cell undifferentiated pattern, or a tumor 
that has small cell undifferentiated and fetal histology [11]. 
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3. Molecular alteration in HB 
Genetic alterations in several chromosomes were identified, for instance, the gains of 
chromosomes 1q, 2q, 2p, 6q, 8q, 17q and 20q, and losses of chromosome 4q [12]. 
Recently, Cairo and his group [13] found that gains on chromosomal region 8q and 2q 
were associated with a C2 subclass of HB. It is named C1 and C2 by using gene 
expression profiling this group that identified two subclasses of HB tumors. C1 and C2 
exhibit similarity with distinct phases of liver development. Compared to the fetal-like C1 
subclass, C2 conforms to an proliferate faster embryonal histotype. In addition, the group 
investigated that the C2 tumors display intensive nuclear accumulation of β-catenin and 
the cell cycle related genes are highly expressed. They introduced a 16-gene signature 
which classify the tumors into C1 and C2 subclasses based on the most differentially 
expressed genes [13]. Remarkably, the 16-gene signature can not only predicted 
prognosis with high accuracy, but also discriminates invasive and metastatic HB [14].  
Recently, Gröbner et al. analyzed 24 types of adult cancer entities and all major childhood 
cancer entities and proved that HB has the lowest mutation rate among all kinds with 
about 4 mutations per tumor [15]. Notably, among all abnormal signaling pathways in HB, 
β-catenin mutations [16, 17] present with the highest rate (50-90%). Moreover, the Wnt/β-
catenin signaling pathway plays a wildly known major role in hepatic-related tumor 
development. Other important signaling pathways in HB genesis are AKT-signaling and 
the LIN28B/let-7 pathway, which are also altered in many kinds of human cancers. 
 
4. Wnt signaling pathway  
4.1 Role of Wnt signaling pathway  
Wnt signaling is an essential factor in liver homeostasis as well as liver tumorigenesis. 
Examples for its physiological role are: i) the canonical Wnt signaling has been found to 
be not activated in adult liver except for hepatic lobule in centri-zonal region [18], ii) the 
reactivation of the Wnt pathway occurs during liver regeneration in adults [19], and iii) the 
β-catenin protein level increases about 2.5 fold in response to the injury induced by partial 
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hepatectomy during the early minutes. Moreover, Wnt signaling is involved in many 
human cancers, such as non-small cell lung cancer [20], colorectal cancer [21], breast 
cancer [22], and particularly interest liver cancer [23].  
In Wnt off state, a complex including Adenomatous Polyposis Coli (APC), AXIN, casein 
kinase Ia (CKIa), and the glycogen synthase kinase 3β (GSK3β) leads to β-catenin 
phosphorylation. The β-catenin is then ubiquitinated by Beta-Transducin repeat 
Contaning E3 Ubiquitin Protein Ligase (βTRCP) and targeted for proteasome-mediated 
degradation [24]. In the absence of β-catenin, a complex containing T-cell factor/lymphoid 
enhancer factor (TCF/LEF) recruits Histone Deacetylases to repress target genes. When 
Wnt pathway is activated, the canonical Wnt signal is transduced through Frizzled (FZD) 
family receptors to coreceptor LRP5/6, since it induces FZD-DVL complex and LRP5/6-
AXIN-FRAT complex assembly [25, 26], β-catenin then gets stabilized, shuttles to the 
nucleus and accumulates there. Nuclear β-catenin then complexes with (TCF/LEF) family 
transcription factors, at the same time with Legless family docking proteins (BCL9 and 
BCL9L) associated with PYGO family [27]. Finally, the TCF/LEF-β-catenin complex in the 
nucleus acts as effector to activate transcriptional target genes such as MYC, AXIN2, 
DKK1, and cyclin D1 [28].  
 
4.2 Wnt/β-catenin in hepatoblastoma  
Activation of the Wnt signaling pathway (Figure.2) is prevalent in HB, occurs in both 
embryonal and mixed types. The Wnt signaling pathway has also been observed as a 
major activated pathway in both proliferative stem cells and neoplasm, which makes it 
intelligible that Wnt signaling has a specific role in embryonic tumors [29]. Wnt signals are 
shifted to canonical Wnt signaling for cell fate determination [30-33], while to the non-
canonical Wnt signaling for controlling cell movement and tissue polarity. Terrada et al. 
[14] found that different β-catenin status correlated with HB histologic subtypes and also 
that CTNNB1 mutation were occasionally absent in Wnt signaling pathway activation [34]. 
The CTNNB1 mutational mechanisms that have been frequently discovered can differ, 
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with more than half of them accounting for deletions in HB [12, 13, 35]. Moreover, the β-
catenin key working mechanism is its stability and accumulation in the cytoplasm.   
 
 
Figure. 2 The canonical Wnt signaling pathway. Wnt off state: The ubiquitin-dependent degradation 
of β-catenin phosphorylated by the destruction complex (AXIN-APC complex). Subsequently, TCF 
transcription factors are repressed and then Wnt target gene expression is inhibited. Wnt on state: β-
catenin is predominantly accumulated in the cytoplasm and translocated into the nucleus, where it 
binds to LEF/TCF and further activates expression of Wnt target genes, such as c-Myc, cyclin D1, 
Axin2, and Dkk1. Figure is taken from Yang et al. [36]. 
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5. The LIN28B/let-7 network 
5.1 LIN28B/let-7 
LIN28 is a RNA binding protein has two forms: LIN28A and LIN28B, located on 
chromosome 1 and 6, respectively [37]. LIN28A is a translational enhancer, while LIN28B 
is a nuclear primary inhibitor of miRNA biogenesis. LIN28B is known as a RNA binding 
protein that influences metabolism, stem cell maintenance, and oncogenesis. It is alone 
sufficient to drive cancer [38]. LIN28B has been proven to be associated with a more 
aggressive, embryonic tumor type characteristic of an oncofetal gene expression program 
[39]. This study also reported that the overexpression of LIN28B is sufficient for initiating 
HB and HCC in murine models.  
The miRNA pathway evolutionarily plays vital roles in various aspects of biology. There is 
a highly conserved miRNA let-7 belongs to the initial class of miRNAs, which targets the 
translation of RNA binding protein LIN28B. The ongoing research has uncovered 
extensive co-regulation between these genes [40]. Due to the differential subcellular 
localization of LIN28A and LIN28B, let-7 blocking process in different steps of the miRNA-
processing pathway were proved by human cancer cell lines [41]. However, the steps 
where let-7 is blocked are controversial. Several studies that already demonstrated the 
strong correlation of LIN28B overexpression and let-7 loss with poor prognosis [42]. Let-
7 miRNA, as a tumor suppressor, targets several oncogenes such as MYC, HMGA2 and 
cyclin D1 [43]. As one of the let-7 targets, LIN28B precise mechanism responsible for let-
7 inhibition is controversial. LIN28B command its biological functions upon repressing the 
let-7 miRNA family as well as modifying these mRNAs translation efficiency. Although the 
inhibition of LIN28B can regress established xenograft human tumors in mice, further 
studies are still needed to precisely define the responsible mechanisms of LIN28B-
mediated let-7 repression.  
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5.2 TRIM71  
One important protein that regulates LIN28B/let7 signaling is TRIM71 (Tripartite Motif 
Containing 71), also named LIN41 (Abnormal Cell LINeage 41). It is a protein-coding gene 
that encodes an E3 ubiquitin-protein ligase that binds to miRNAs [44]. TRIM71 belongs to 
the TRIM-NHL family, containing a RING domain, a CC domain, a BB domain, and a NHL 
domain. Its functional activity as E3 ubiquitin ligase is associated with the RING domain. 
Moreover, the NHL domain is related to its miRNA binding activity [45]. TRIM71 binds to 
a miRNA, complexes with AGO2, which participates in post-transcriptional repression of 
transcripts, such as CDKN1A. TRIM71 can additionally participate in post-transcriptional 
mRNA repression by a miRNA independent mechanism [46]. By repressing CDKN1A 
expression, the G1-S transition was stimulated to promote rapid embryonic stem cell self-
renewal. It has been reported in mammalian cells that TRIM71 could be taken instead of 
MYC in the canonical reprogramming complex containing OCT4, SOX2, and KLF4, to 
invert fibroblasts into induced pluripotent stem cells (iPS) [47]. It was demonstrated in 
previous studies that direct binding of MYC, the key downstream target of Wnt signaling, 
to the TRIM71 promoter enhances TRIM71 expression, which suggests TRIM71 as a 
MYC effector [48].  
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Figure. 3 LIN28 affects let 7 maturation via several methods. TRIM71 inhibits LIN28A, which binds 
to pre-let 7 for preventing cleavage by Dicer. TRIM71 can also inhibit LIN28B, that can bind to pri-let 7 in 
the nucleus thereby preventing cleavage by Drosha. Figure from McDaniel et al. [49]. 
Yin et al. claimed that TRIM71 is the top modulator of the LIN28B-let 7-HMGA2 pathway, 
and therefore serves as an essential factor in tumor formation, tumorigenesis, and 
malignancy [50]. By performing knock-down experiments in Caco-2, Tera-1, NCI-H1299, 
and NCI-H460 cancer cell lines using siRNA specific for TRIM71, they found that TRIM71 
inhibits LIN28B. Also, TRIM71 can be activated by up-regulation of let-7, which inhibits 
both LIN28A and LIN28B in the feedback mechanism (Figure.3)[51]. Let-7 high 
expression is associated with decreased LIN28 A/B expression. Interestingly, this 
inhibition of LIN28 A/B can be accomplished by let-7 through activation of TRIM71, which 
targets both forms of LIN28 for ubiquitin-mediated proteasomal degradation [52].  
Interestingly, TRIM71 was identified as a novel oncogene in human HCC and associated 
with poor prognosis [48], which was deduced from several findings: TRIM71 is frequently 
overexpressed in HCC, TRIM71 enhances tumor growth, proliferation, and tumorigenicity 
of HCC, and TRIM71 can activate let-7 dependent oncogenesis. According to this paper, 
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TRIM71 could serve as an ideal target for liver cancer treatment. However, so far there 
are no studies that describe a potential role of TRIM71 in other types of liver cancer. An 
involvement of TRIM71 in HB genesis and a possible connection of the Wnt signaling 
pathway and the LIN28B pathway need to be elucidated.  
 
6. Aim of the study 
In this study, we mainly aim to characterize the role of TRIM71 in HB and HCC, the two 
major childhood liver tumor types. We wanted to: 
o characterize the biological function of TRIM71 in liver tumors on the cellular level 
o explore the clinical relevance of TRIM71 for varying outcomes of HB patients 
o describe the molecular mechanisms how TRIM71 integrates into the Wnt signaling 
pathway   
Materials 
 
11 
Materials  
1. Cell lines 
HepT1, Homo sapiens, HB                                Pietsch et al. [53] 
HUH6, Homo sapiens, HB                             JCRB, Osaka, Japan 
Hep3B, Homo sapiens, HB                           ATCC, Manassas, USA 
HUH7, Homo sapiens, HCC                           ATCC, Manassas, USA 
 
2. Cell culture materials 
RPMI                                     Invitrogen, Karlsruhe, Germany 
PS (10,000 U/ml)                           Invitrogen, Karlsruhe, Germany 
DPBS                                     Invitrogen, Karlsruhe, Germany 
FCS                                         Invitrogen, Karlsruhe, Germany 
Trypsin-EDTA 0.05%                       Invitrogen, Karlsruhe, Germany 
Costar Stripette Serologic Pipettes 5ml     Corning GmbH, Wiesbaden, Germany 
Costar Stripette Serologic Pipettes 10ml    Corning GmbH, Wiesbaden, Germany 
Costar Stripette Serologic Pipettes 25ml    Corning GmbH, Wiesbaden Germany 
Biosphere Filtertips 1-10 µl            Sarstedt AG & Co., Nümbrecht, Germany 
Biosphere Filtertips 10-100 µl          Sarstedt AG & Co., Nümbrecht, Germany 
Biosphere Filtertips 100-1000 µl        Sarstedt AG & Co., Nümbrecht, Germany 
Cell culture T-Flasks 25m2                           NUNC, Langenselbold, Germany 
Cell culture T-Flasks 75m2                    NUNC, Langenselbold, Germany 
Falcon tubes 15ml                   Greiner bio-one, Frickenhausen,Germany 
Falcon tubes 50ml                   Greiner bio-one, Frickenhausen,Germany 
DNase and RNase free                       NUNC, Langenselbold, Germany 
Petri dishes 100mm                          NUNC, Langenselbold, Germany 
6-well Plates, non-pyrogenic                  NUNC, Langenselbold, Germany 
12-well Plates, non-pyrogenic                 NUNC, Langenselbold, Germany 
Materials 
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24-well Plates, non-pyrogenic                 NUNC, Langenselbold, Germany 
96-well Plates, non-pyrogenic                 NUNC, Langenselbold, Germany 
Cell scraper                         Sarstedt AG & Co., Nümbrecht, Germany 
Glastips                             Sarstedt AG & Co., Nümbrecht, Germany 
 
3. Bacteria 
Escherichia coli DH5α                         Invitrogen, Karlsruhe, Germany 
 
4. Plasmids 
pcDNA3-FLAG-TRIM71               Prof. Dr. Jong Heon Kim, Goyang, Korea 
      pEGFP-N1                               ClonTech, Mountain View, CA, USA 
      pUC19                               Prof. Dr. Heiko Hermeking, LMU Munich 
      pRTR                    Prof. Dr. Heiko Hermeking, LMU Munich 
      pRTR-FLAG-TRIM71                           M. Med. Ting Jiang, this study 
  
5. Enzymes 
      RnaseA                                   Sigma-Aldrich, St.Louis, MD, USA  
      DNaseI                                   Sigma-Aldrich, St.Louis, MD, USA  
       ProteinaseK                               Sigma-Aldrich, St.Louis, MD, USA 
      Restriction endonucleases     New England Biolabs GmbH, Frankfurt, Germany  
      T4 DNA ligase                New England Biolabs GmbH, Frankfurt, Germany  
      Klenow Fragment             New England Biolabs GmbH, Frankfurt, Germany 
      Sfill                          New England Biolabs GmbH, Frankfurt, Germany 
      Scal                         New England Biolabs GmbH, Frankfurt, Germany 
Xbal                         New England Biolabs GmbH, Frankfurt, Germany 
Kpnl                         New England Biolabs GmbH, Frankfurt, Germany 
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Notl                         New England Biolabs GmbH, Frankfurt, Germany 
Sacl                         New England Biolabs GmbH, Frankfurt, Germany 
SuperScript II Reverse Transcriptase            Invitrogen, Karlsruhe, Germany 
Taq DNA polymerase                       Sigma-Aldrich, St Louis, MD, USA 
 
6. Antibodies 
Anti-β-catenin, Rabbit, WB                    Epitomics, Burlingame, CA, USA  
Anti-β-actin, Rabbit, WB               Cell signaling technology, Danvers, USA 
Anti-LIN41, Sheep, WB                   R&D SYSTEMS, Frankfurt, Germany 
Anti-Flag, Mouse, WB                       Sigma-Aldrich, St.Louis, MD, USA 
Anti-mouse HRP, WB                       Sigma-Aldrich, St.Louis, MD, USA  
Anti-rabbit HRP, WB                        Sigma-Aldrich, St.Louis, MD, USA  
Anti-sheep HRP, WB                         Novex, Thermo Fisher, OR, USA 
 
7. Kits 
Quick Blunting Kit             New England Biolabs GmbH, Frankfurt, Germany 
QIAprep Spin Miniprep Kit        QIAprep Spin Miniprep Kit, Frankfurt, Germany 
QIAquick Gel Extraction Kit       QIAprep Spin Miniprep Kit, Frankfurt, Germany  
QIAprep Spin Midiprep Kit        QIAprep Spin Miniprep Kit, Frankfurt, Germany  
QIAquick PCR Purification Kit     QIAprep Spin Miniprep Kit, Frankfurt, Germany 
 
8. Buffer and solutions 
RIPA Protein Lysate Buffer 
• 1% NP40  
• 0.5% sodium deoxycholate  
• 0.1% SDS  
Materials 
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• NaCl 150 mM  
• 50 mM TrisHCl (pH 8.0)  
 
Tris-glycine –SDS Running Buffer 10X 
•  14.4% glycine  
•  3% Tris base  
•  1% SDS  
•  pH 8.3-8.7  
 
PBS-T Buffer 1X 
• 50% 2xPBS 
• 0.1% Tween 20 
 
Blocking Solution 
• 3-5% dry milk in ddH2O  
 
Laemmli Buffer 2X 
• 125 mM TrisHCl (pH 6.8)  
• 4% SDS  
• 20% glycerol  
• 0.05% bromophenol blue (in H2O)  
• 10% beta-mercaptoethanol  
 
MTT-1 Solution 
• 4 mM HCl 
Materials 
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• 0.1% NP40 
• Adjust with PBS 
 
MTT-2 Solution 
• 10% SDS 
• 37% HCl 
 
Freezing Medium 
• 48.8% FCS 
• 39% DMEM 
• 12.2% DMSO 
 
9. Primers 
Name Ref Seq No. Forward Reverse 
TRIM71 NM_001039111.2 GCTGTGGAAGGTAGAAAAGA
TCC 
GCTTGTTGAGGTTTTGCCG 
TRIM71-seq NM_001039111.2 GGTGGCTGACAAGGACATC GCTTGTTGAGGTTTTGCCG 
LIN28B NC_000006.12 AGCCCCTTGGATATTCCAGTC AATGTGAATTCCACTGGTTCTCC
T 
IGF2BP1 NC_000017.11 CCAAGAGACCAGACCCCTGA AGGATGTCTCGGATCTTCCGT 
HMGA2 NC_000012.12 ACCTAGGAAATGGCCACAAC
A 
GCGCCCCCTAGTCCTCTTC 
DKK1 NM_012242.2 GTCACGCTATGTGCTGCCC GTTTCCTCAATTTCTCCTCGGA 
CTNNB1 NM_001904.2 ACGTCCATGGGTGGGACA CTAGGATGTGAAGGGCTCCG 
AXIN2 NM_004655.2 TATCCAGTGATGCGCTGACG TGTTTCTTACTGCCCACACGAT 
Materials 
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LGR5 NC_000012.12 ACAGCAGTATGGACGACCTT
CA 
CAGGTCTTCCTCAAAGTCAAGCA 
TBP NM_003194.3 GCCCGAAACGCCGAATAT CCGTGGTTCGTGGCTCTCT 
 
10. Chemicals and Reagents  
Milchpulver                                   Carl Roth, Karlsruhe, Germany 
Dithiothreitol DTT (0.1 M)                      Invitrogen, Karlsruhe, Germany 
dNTPs                           Thermo Fisher Scientific, Waltham, MA, USA  
Magnesium chloride                           Carl Roth, Karlsruhe, Germany 
SYBR Green Master Mix                        BIO-RAD, Stuttgart, Germany 
Tween20                                Sigma-Aldrich, Steinheim, Germany 
MTT formazan powder                     Sigma-Aldrich, Steinheim, Germany 
Isopropyl alcohol                          Sigma-Aldrich, Steinheim, Germany 
EDTA                                        Carl Roth, Karlsruhe, Germany  
FuGENE Transfection Reagent                   Promega, Madison, WI, USA 
Sodium dodecyl sulfate                        Carl Roth, Karlsruhe, Germany 
Water (DNase/RNase-Free)       Life Technologies GmbH, Ismaning, Germany  
Crystal Violet                                 Carl Roth, Karlsruhe, Germany 
Ethanol, absolut                                 Merck, Darmstadt, Germany 
Chloroform                                   Carl Roth, Karlsruhe, Germany 
Bromophenolblue                              SERVA, Heidelberg, Germany 
Agarose                                       PeQLab, Erlangen, Germany 
TRI Reagent RNA Isolation Reagent        Sigma-Aldrich, Steinheim, Germany 
Nonidet P40 Substitute                      Sigma-Aldrich, St.Louis, MD, USA 
Opti-MEM                      Life Technologies GmbH, Darmstadt, Germany 
Gene Ruler 1kb DNA ladder                   Fermentas St.Leo-Rot, Germany 
Page Ruler Prestained Protein Ladder          Fermentas St.Leo-Rot, Germany 
Western Blot Protein Standard                   BIO-RAD, Stuttgart, Germany 
siGENOME Human TRIM71 siRNA smart pool   Dharmacon, Lafayette, CO, USA 
Lipofectamine 2000               Thermo Fisher Scientific, Waltham, MA, USA 
Materials 
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Random hexameric primers        Thermo Fisher Scientific, Waltham, MA, USA 
 
11. Consumables  
Biosphere Filtertips                   Sarstedt AG & Co., Nümbrecht, Germany 
Pipette tips (10ul, 100ul, 1000ul)                Sarstedt, Nümbrecht, Germany      
PCR 96 Well Plates                             PeQLab, Erlangen, Germany 
4-20% Tris-Glyci Gels                         Invitrogen, Karlsruhe, Germany 
Safe-lock Eppendorf tube                      Eppendorf, Hamburg, Germany 
Quarz cuvette QS 10.00 mm                      Hellma, Muellheim, Germany 
Trans-Blot Turbo Mini PVDF Transfer Packs       BIO-RAD, Stuttgart, Germany 
Multidishes Nunclon                         NUNC, Langenselbold, Germany 
Hyperfilm ECL                             Sigma-Aldrich, St. Louis, MD, USA 
 
12. Equipment 
Table-top Centrifuge                       Eppendorf AG, Hamburg, Germany 
Axiovert 40 Microscope               Carl Zeiss GmbH, Oberkochen, Germany 
Biofuge Centrifuge                 Thermo Fisher Scientific, Inc, Waltham, USA 
CF 40 Imager                              Kodak, Rochester, New York, USA 
Trans-Blot Turbo Transfer System                BIO-RAD, Stuttgart, Germany 
Biofuge pico, Heraeus                       Kendro, Langenselbold, Germany 
Camera Power Shot G6                             Canon, Krefeld, Germany 
Centrifuge 5702                              Eppendorf, Hamburg, Germany 
Centrifuge J2-21                          Beckman Coulter, Krefeld, Germany 
Centrifuge LMC-3000                           G. Kisker, Steinfurt, Germany 
Heat block MR 3001                            Heidolph, Kehlheim, Germany 
Heatblock Thermomixer comfort                Eppendorf, Hamburg, Germany 
Microwave                                   Panasonic, Hamburg, Germany 
NanoDrop 1000 instrument                 Thermo Scientific, Wilmington, USA 
Materials 
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Shaker, Rock-N-Roller                          G. Kisker, Steinfurt, Germany 
Shaker, Unimax 1010                         Heidolph, Schwabach, Germany 
Western-Blot Detection DIANA                         AGFA, Köln, Germany 
Water bath GFL 1083                                    GFL, Wien, Austria 
Vortexer Genie2                               Scientific Industries, NY, USA 
CO2-Incubator MCO-20AIC                             Sanyo, Tokyo, Japan 
Agarose gel electrophoreses apparatus              Bio-Rad, Munich, Germany 
Bio Photometer                               Eppendorf, Hamburg, Germany 
GENios Microplatereader                        Tecan, Crailsheim, Germany 
Mastercycler ep gradient S                     Eppendorf, Hamburg, Germany 
Micro scales Te1245                           Sartorius, Göttingen, Germany 
XCell SureLockTM Electrophoresis Cell          Invitrogen, Karlsruhe, Germany 
 
13. Software 
ImageJ Software                                   NIH, Bethesda, MD, USA 
GraphPad Prism 6                                        La Jolla, CA, USA 
Microsoft Office 2010                              Microsoft, Redmond, USA  
Chromas                      Technelysium Pty Ltd, South Brisbane, Australia  
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Methods 
1. Cloning 
The Flag-tagged full-length coding sequence of human TRIM71 was released from the 
pcDNA-TRIM71-Flag plasmid [54] by digestion with Sacl-Xbal and then integrated into the 
pUC-easy shuttling vector using the Quick Blunting Kit. TRIM71-Flag was then released 
from the shuttling vector by a digest with Sfil-Scal and inserted into the pRTR (Sfil) vector. 
Sequence verification was performed by Sanger sequencing in the Sequence Service at 
the Faculty of Biology from LMU. 
Sequencing primers:  
TRIM71-seq forward, 5’-GGTGGCTGACAAGGACAATC-3’ 
TRIM71-rev reverse, 5’-CGACGACGTGGACGTCTGCG-3’ 
 
2.  Transformation 
E.coli aliquots were thawed on ice and 100ng of plasmid DNA was added to bacteria. 
Without vortexing, cells were incubated on ice for 30mins, then heat-shocked at 42°C for 
40seconds and put back on the ice for 2mins. 250ul pre-warmed SOC medium was added 
and incubated at 37°C for 1hour with 500rpm rotation. Bacteria were seeded on agar 
plates containing either ampicillin or kanamycin antibiotics. Plates were incubated at 37°C 
overnight. 
 
3. Purification of plasmid DNA from E.coli 
Small amounts of plasmid DNA were isolated using the mini-prep plasmid DNA extraction 
kit. Single colonies from agar plates were inoculated in 5ml LB-medium, supplemented 
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with the respective antibiotics. Overnight cultures were pelleted by centrifugation at 
8,000rpm for 10mins at room temperature. Pellet was resuspended by adding 250ul of 
Buffer P1 and transferred to a 1.5ml tube. Next, 250ul Buffer P2 was added and mixed 
thoroughly by inverting the tubes 4-8 times until the solution becomes clear. Then, 350ul 
Buffer N3 was added, mixed thoroughly and centrifuged for 10mins at 13,000rmp in the 
microcentrifuge. Supernatant from the last step was applied to the QIAprep spin column, 
spinned and washed by 500ul Buffer PB. Flow-through after centrifuging was discarded 
and the spin column again washed with 750ul PE. Residual wash buffer was removed by 
centrifuging, and the DNA eluted into a new 1.5ml tube using Buffer EB. To yield a larger 
amount of DNA, the Midiprep system and bacteria cultures of 150ml to 200ml were used.  
 
4. RNA-extraction and reverse transcription 
All investigated cells were harvested after 48hours seeding. Total RNAs were isolated 
from cells using TRIzol reagent according to the manufacturer’s protocol, RNA 
measurement was performed by nanodrop. cDNAs were synthesized from 2ug RNA with 
random hexameric primers and SuperScript II.  
 
5. Real-Time qPCR 
For each qPCR profiling, 40ng of cDNA-synthesis reaction was used with 500nM of primer 
pairs and universal SYBR green supermix in 20ul reaction volume. Cycling consisted of 
40 cycles with denaturation at 95°C for 15 seconds, annealing at 59°C for 15 seconds, 
and elongation at 72°C for 30 seconds proceeded in Mastercycler. Each experimental 
data was assayed in duplicate. Relative expression of candidate genes was calculated 
using the △△Ct method and TBP as a housekeeping gene [55].  
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6. Protein extraction and western blot  
Cells were scraped from the cell culture plates with a scraper after 48h treatment, washed 
twice with ice-cold PBS, and lysed with RIPA lysis buffer. Protein concentration was 
determined at absorbance mode with 595nm wavelength using Bradford assay. 
Approximately 20-40ug proteins were loaded into 4-20% gels and separated by 
electrophoresis at 200V/110mA. Afterwards, gels were electroblotted onto PVDF 
membranes. The membranes were blocked in 5% milk/PBS-T solution for at least 2 hours, 
followed by overnight incubation with primary antibodies against selected proteins. After 
that, blots were washed with PBS-T for 3 X 10mins and incubated at room temperature 
for 1hour with peroxidase-conjugated anti-rabbit or anti-sheep IgG antibody. Ultimately, 
using enhanced chemiluminescence reaction blots were detected and ß-actin served as 
the loading control. Western blot band intensity was quantified by ImageJ software. The 
ratio of values of candidate proteins was normalized to housekeeping protein β-actin. 
 
7. Cell culture 
Two human hepatocellular carcinoma cell lines (HUH7 [56, 57] and Hep3B [58]), and two 
human hepatoblastoma cell lines (HUH6 [59] and HepT1 [53]) were used in this study. 
Cells were grown in RPMI supplemented with 10% FCS and 1% PS and incubated at 
37°C in a humidified incubator with 5% CO2. Cells were passaged every 2-4 days in order 
to avoid confluence. For long term preserving the cell lines, they were regularly maintained 
in a liquid nitrogen tank.  
 
8. Transfection  
Overexpression experiments were performed with FuGENE HD Transfection Reagent. 
On the day of transfection, cells were trypsinized, counted and expected cells were 
transferred to a plate at the confluence at 70%-80%, incubated overnight. The plasmid 
DNAs were mixed with FuGENE at ratio of 1:3 diluted with RPMI, the amount of plasmid 
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DNAs referred to the FuGENE® HD Protocol Database website. Transfection complex 
was then dropped into the cells in medium (containing FCS and PS). The total transfection 
solutions in 50ml falcon were fully mixed on the shaker for 5mins at 150rpm in room 
temperature [60]. Cells were seeded into the plates afterward and medium changed on 
the next day.   
Knockdown experiments were performed either by electroporation or lipofectamine2000 
using the siGENOME SMARTpool si-TRIM71 (Target Sequence: 
GGAGGAGGGUAGAGCGCUA, AGAAGUAGUGCUAGCCGA, 
CUUGGGAUGUGGCGGUGAA, CACCAAGGCCACAGGCGAU). For electroporation, 
objective HUH6 and HUH7 cell number in RPMI medium without PS at the density of 
6666.66 cells/µl together with 1% siRNA were transferred to electroporation cuvettes and 
electroporated at 350V for 10ms. For the lipofectamine2000 method (6-well plate were 
used here) oligomer-Lipofectamine2000 complexes were prepared with 100pmol siRNA 
oligomer in 250ul RPMI (without serum), and diluted 5µl lipofectamine2000 in 250µl RPMI 
(without serum). The two complexes were then incubated for 5mins at room temperature 
separately. Combined the diluted oligomer with lipofectamine 2000 complexes gently and 
incubated for 20mins at room temperature. The total complexes were added to each well 
containing cells and medium. And cells were incubated at 37°C for 24-96 hours until 
assays were ready. The medium was changed after 4-6 hours. 
 
9. Proliferation assay 
5,000 cells/well were seeded into 96-well plates and then transfected either with plasmid 
or siRNA as indicated above. MTT1 solution was added into each well (10µl/well) and 
incubated at 37°C for 4hours. Then MTT2 solution was added to each well (100µl/well). 
Remember the time point of adding two solutions and proceeded at the same time in 
following days. After the last time of processing MTT2, the plates were kept at room 
temperature overnight in the dark and the absorbance at 595nm was measured next day. 
Each experiment was realized 2 times and each condition was done in duplicates.  
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10. Scratch (Migration) assay 
Cells were seeded at a density of 70%-80% per 6-well plate. A scratch was made into the 
confluent cell layer with a 10µl sterile pipette tip and the medium was changed for 
eliminating scratched cells. Pictures were collected from the scratch every 24h with the 
camera attached to the microscope. The gaps’ area was quantified by ImageJ. 
 
11. Colony formation assay 
Both control and treated cells were seeded in 6-well plates with 5,000 cells per well. 
Medium (containing 10% FCS and 1% PS) was changed every second day. Cells were 
collected after 10 days and then fixed with 99% methanol 2 times for 5mins at room 
temperature. Afterwards, cells were stained with crystal violet (0.5% crystal violet mixed 
with 20% methanol) for 1 hour. Colonies were counted with ImageJ.  
 
12. Statistical analysis 
Results are given as mean ± standard error of the mean (SEM). All statistical comparisons 
were done using Student’s T-test cooperating with Welch’s correction and one-way 
ANOVA test. F-test was taken for expression analyses. Correlation analyses were made 
by Pearson correlation. Kaplan-Meier estimates of specific survival time were compared 
using the log-rank Mantel- Cox test. For all comparisons, the criterion for significance was 
p < 0.05 (significant) and p < 0.01 (highly significant).  
Results 
 
24 
Results 
1. TRIM71 is highly expressed in hepatoblastoma 
To clarify the expression of TRIM71, RT-PCR was performed in 10 normal and 31 tumor 
samples as well as 4 liver tumor cell lines. We found TRIM71 significantly upregulated in 
HB tumor samples and 4 tumor cell lines compared with normal liver samples (Figure 4). 
HUH6 and HUH7 cells showed relatively high, while HepT1 and Hep3B relatively low RNA 
levels.   
 
Figure. 4 Expression of TRIM71 in hepatoblastoma, normal liver and liver tumor cell lines. 
TRIM71 mRNA levels were shown as the relative expression in 10 normal liver samples (NL), 31 liver tumors 
(TU), and 4 cell lines (CL). The analysis was performed by RT-PCR and normalized with the housekeeping 
gene TBP. Groups were compared by Student T-test and significance was considered if *p < 0.05.  
 
2. TRIM71 overexpression inhibits cell proliferation in human HB cell lines 
MTT assay was applied to further investigate the function of TRIM71. We performed gain-
of-function experiments in HepT1 and Hep3B cell lines, which we know are TRIM71 low 
expressing cells (Figure.5). Likewise, loss-of-function experiments were operated in 
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HUH6 and HUH7 cell lines, which express high levels of TRIM71. Interestingly, TRIM71 
overexpression suppressed the viability of HepT1 and Hep3B cells, although this was only 
significant in HepT1, while its downregulation stimulated cell proliferation at least in HUH6 
cells. These results indicate that TRIM71 can inhibit cell proliferation in liver tumor cells. 
 
Figure. 5 TRIM71 induces growth inhibition in HB cells. Cell viability assays in human HB and HCC 
cell lines. HepT1 and Hep3B cells were transfected with TRIM71 expression and control plasmid. HUH6 
and HUH7 were treated with TRIM71 knockdown by siGENOME Human TRIM71 smart pool. Cell viability 
was measured by MTT assays at the time points indicated. The mean and SEM of 3 independent 
experiments was calculated (lower row). The transfection efficiency was tested by measuring the relative 
TRIM71 expression normalized to the house-keeping gene TBP by RT-PCR. Significance levels are as 
followed: *p < 0.05. 
 
3. TRIM71 does not affect apoptosis in pediatric hepatic tumors 
In order to assess if the lower proliferation rate provoked by TRIM71 is based on 
modulation of apoptosis, the apoptotic marker PARP was detected by western blot. Cells 
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were treated with TRIM71 overexpression and knockdown and protein lysates were 
collected after 2 days. There is no difference between each pair of control and treated 
samples. Thus, it seems that the apoptotic machinery is not associated with TRIM71-
induced growth variations (Figure 6).  
 
Figure.6 Hepatic cells show no apoptosis depending on TRIM71 induction or reduction. 
Apoptosis was analyzed by detecting PARP protein with western blot. All 4 cell lines were treated either 
with TRIM71 overexpression or knockdown, and protein was isolated after 2 days. Western blot was done 
against PARP, and β-actin served as a housekeeping protein.  
 
4. TRIM71 does not affect hepatic cell migration 
The cell migration ability was determined by monitoring the time cells need to close a gap 
that has been introduced by scratching a confluent cell layer. TRIM71 overexpression and 
knockdown showed no significant difference in time of gap closing. Hence, these data 
suggest that TRIM71 does not influence cell growth by impacting migration (Figure 7).  
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Figure. 7 TRIM71 has no impact on hepatic cell migration. Four cell lines (HepT1, Hep3B, HUH6, 
HUH7) were treated either with TRIM71 expressing plasmids or knockdown-mediating siRNA and the gap 
was measured at the indicated time points (top panel). mRNA expression performed with RT-PCR 
normalized by the housekeeping TBP (middle panel). Pictures were taken every 24 hours at the same point 
and the area calculated by ImageJ. Representative pictures of the scratch assays are show in the bottom 
panel. Differences in the time points are based on the varying growing speed of the different cell lines. 
Significance levels are as followed: *p < 0.05. 
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5. TRIM71 does not interfere with E-cadherin 
TRIM71 showed no impact on migration as described above. E-cadherin (CDH1) is 
known to play a main role in cell adhesion and is essential for preventing cell migration. 
Thus, we analyzed CDH1 at the protein level by western blot. It is obvious that CDH1 
was unchanged upon TRIM71 induction or reduction. Of note, CDH1 showed stronger 
signals in HepT1 and HUH6 cells, the two HB cell lines (Figure.8). 
 
Figure. 8 E-cadherin western blot showed no difference upon TRIM71 modulation in HB and 
HCC cell lines. E-cadherin abundance was determined in TRIM71 induced and reduced conditions. 
Western blot was performed after 2 days with antibodies against E-cadherin/CDH1 and β-actin as a loading 
control.  
 
6. TRIM71 overexpression stimulates the capacity of hepatic tumor cells to 
produce colonies 
TRIM71 has been recently shown to play an essential part in cell self-renewal [61]. Thus, 
clonogenic assays were performed after TRIM71 overexpression and knockdown to 
determine the ability of liver tumor cells to produce cell colonies. Our experiments clearly 
show that the human hepatic cell lines with TRIM71 overexpression have a stronger self-
renewal capacity as control transfected cells. In contrast, knockdown of TRIM71 led to a 
significant suppression of the colony producing capacity (Figure.9).   
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Figure. 9 Low expression of TRIM71 reduces the capacity of producing colonies. The impact of 
TRIM71 on colony formation was investigated by clonogenic assays. Four cell lines were treated with 
transient transfection of either an overexpression plasmid or knockdown-mediating siRNAs. Colonies were 
fixed and stained after 10 days of incubation. Each column represents the number of colonies of the treated 
cells normalize to the control cells. Significance was considered at: *p < 0.05, **p < 0.01, ***p< 0.001. 
 
7. Genes of the let-7/ LIN28B network are highly expressed in HBs 
To further investigate if genes of let7/LIN28B network are concomitantly altered with 
TRIM71 in their expression, mRNA levels of LIN28B, HMGA2 and IGF2BP1 were 
evaluated by RT-PCR (Figure.10). Compared with normal liver tissue, all 3 genes are 
highly expressed. Of note, HMGA2 and IGF2PB1 expression was also significantly higher 
in liver tumor cell lines.  
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Figure. 10 Expression analysis of let-7/LIN28B network genes in HB and HCC. mRNA expression 
analysis performed by RT-PCR that showed relative candidate gene expression normalized to TBP 
housekeeping gene in 31 primary tumors (TU), 10 normal livers (NL) and 4 tumor cell lines (CL). Groups 
were compared using Student T-test and significance was considered at: *p < 0.05, ** p < 0.01. 
 
8. TRIM71 is highly correlated with let-7/LIN28B network genes  
The correlation analysis was performed to verify the hypothesis of a close relationship 
between the let-7/LIN28B network genes and TRIM71. Indeed, we found that all 4 genes 
are highly positively correlated with each other, which might indicate that they all play a 
predominant role in the mechanisms of liver cancer (Figure. 11).  
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Figure. 11 The correlation analysis of let-7/LIIN28B network genes. The correlation analysis was 
applied to mRNA expression levels in each combination of the four genes using Pearson correlation. 
Coefficient r values were calculated, and values close to 1 indicate perfect correlation. P-values were 
calculated and significance was considered at *p < 0.05, ** p < 0.01, *** p < 0.001. 
 
9. TRIM71 overexpression is a general phenomenon in hepatoblastoma and only 
associated with CTNNB1 mutations 
In a next step, we stratified the 31 tumor samples according to specific clinical and 
biological features such as sex, age, PRETEXT, vascular invasion, metastasis, 
multifocality, 16 gene signature, and CTNNB1 mutation status (Table 1). In our cohort, 
females (51.6%) and males (48.4%) were nearly equally distributed and most patients had 
an onset of disease within 36 months (74.2%). The proportion of patients with large tumors 
(PRETEXT IV) was 74.2%), with metastasis 35.5%, with multifocal tumor growth 38.7%, 
and with vena cava and portal vein invasion at the time of diagnosis of 12.9% and 16.1%, 
respectively. As expected, most tumors had CTNNB1 mutations (83.9%). The recently 
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discovered 16-gene signature, which is known to be associated with prognosis [62], was 
found to show the C1 type in 61.3%, and the C2 type in 38.7% of patients.  
By comparing the expression level of TRIM71 between the defined clinical groups, we 
found no statistically relevant differences for any clinical parameter (Figure.12), which 
defines TRIM71 overexpression as a general marker for hepatoblastoma. In line with this, 
there was no difference in the prognostic 16-gene signature related to their TRIM71 
expression (Figure.12), as well as in the outcome of patients, as shown by Kaplan-Meier 
analyses for overall and event-free survival (Figure.13). However, we found that there is 
a trend (P=0.0611) toward higher TRIM71 expression in cases with CTNNB1 mutations 
(Figure.14). Interestingly, this was also true for LIN28B (P=0.0701) and HMGA2 
(P=0.1027) expression, whereas for IGF2BP1 (P=0.0188) this association was even 
significant (Figure.14). 
Table. 1 Clinical and biological features of patients 
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Figure. 12 TRIM71 expression in clinical and biological defined subsets of patients. Relative 
genes expression of TRIM71 in 31 primary tumors were grouped according to their clinical and biological 
characteristics. Groups were compared by Mann-Whitney test and the P-values are given.  
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Figure. 13 Kaplan-Meier analyses for overall and event-free survival of TRIM71. The high 
expression is defined as > mean+5-fold standard deviation of 10 normal liver samples. Months stand for the 
time after diagnosed.  
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Figure. 14 Gene expression dependent on the CTNNB1 mutation status. Relative gene expression 
of candidate genes in 31 primary tumors stratified according to their CTNNB1 mutational status (wt = wild 
type, mut = mutated). Groups were compared by Mann-Whitney test and the P-values are given.  
 
10. β-catenin accumulates upon TRIM71 induction in HB cells 
Wnt activation is an important mechanism that drives development of liver tumors [63]. As 
the β-catenin protein is the central component of Wnt signaling and high TRIM71 
expression is associated with CTNNB1 mutations (Figure.14), we investigated if β-catenin 
is altered by TRIM71 modulation by doing western blot. In HepT1 cells, TRIM71 induction 
increased β-catenin protein levels, while in HUH6 cells TRIM71 knockdown led to a 
reduction of β-catenin, indicating that TRIM71 influences β-catenin accumulation. 
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However, this scenario was not seen in the two HCC cell lines Hep3B and HUH7, which 
are known to be wildtype for β-catenin, as opposed to the two HB cell lines HepT1 and 
HUH6 that harbor mutations in the β-catenin gene (Figure.15).  
 
Figure. 15 TRIM71 overexpression accumulates β-catenin in HB cell lines. To determine the β-
catenin abundance in TRIM71 induced and reduced conditions, western blot was performed 2 days after 
treatment. The western blot analysis was done by β-catenin antibody and β-actin served as a loading control.  
 
11. Wnt target gene and LIN28B/let7 pathway expression upon TRIM71 level 
modulation 
To further analyze the association between TRIM71 and Wnt signaling as well as the 
TRIM71-associated LIN28B/let-7 pathway, RT-PCR was performed with three 
independent experiments from each cell line upon TRIM71 overexpression and 
knockdown (Figure.16). The Wnt target genes AXIN2, LGR5, and DKK1 as well as 
CTNNB1 itself showed no significant changes upon either TRIM71 knockdown or 
overexpression. Identically, the LIN28B/let-7 pathway genes LIN28B, HMGA2, and 
IGF2BP1 also remained unchanged (Figure.16). However, it is not surprising considering 
that TRIM71 mainly regulates its targets post-transcriptionally. 
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Figure. 16 Expression analysis of Wnt- and let-7/LIN28B-associated genes upon TRIM71 
modulation. Gene expression was analyzed by RT-PCR and relative candidate gene expression 
normalized to TBP housekeeping gene of 3 independent experiments after TRIM71 overexpression or 
knockdown are shown (mean and standard deviation). Each sample was done in duplicates. The treated 
group was normalized to control and is shown as fold change. Statistical significance shown as follow: *p < 
0.05, ** p < 0.01. 
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Discussion  
1. Why can TRIM71 only repress cell proliferation and accumulate β-catenin in HB 
cell lines? 
Although tumors are heterogeneous, they still all share the ability to proliferate compared 
to the limiting growth of normal tissues. Alterations in key pathways controlling cell 
proliferation including Wnt signaling are mandatory for tumor establishment [64]. In our 
study, proliferation assays performed in four different liver tumor cell lines (2 HB and 2 
HCC) clearly showed that TRIM71 affects proliferation only in the two cell lines HepT1 
and HUH6 that are CTNNB1 mutated, where overexpression and gene knockdown 
resulted in either the reduction or induction of cell growth, respectively. The two HCC cell 
lines with wildtype CTNNB1 instead did not respond on TRIM71 modulation. In recent 
publications, TRIM71 has been found also to inhibit tumor growth in non-small lung 
carcinoma [50]. Other TRIM family members have been discovered to be implicated with 
tumorigenesis as well, for example TRIM8, TRIM11, TRIM16, and TRIM62 [65]. TRIM2, 
TRIM3 and TRIM32 and some other family genes share structural homology in C terminal 
like TRIM71 [66-68]. TRIM3 was reported with NHL domain-dependent cell proliferative 
inhibition, even more, the RING domain was found necessary for tumor suppression. 
TRIM25 has been implicated with the proliferation of many cancer too, while often with 
estrogen response and through a variety of pathways for further promotion [69]. It has 
been published that TRIM25 increased cell proliferation with the requirement of targeting 
a negative cell cycle regulator for degradation [70]. Nevertheless, in our case, TRIM71 
seems to have another unique function than other TRIM members, which mainly depend 
on their epigenetic modulation and E3 ligase activity or their RNA binding property. 
Surprisingly, this significant difference can be only seen in HB cell lines with an activated 
Wnt signaling pathway. So the questions arose, if TRIM71 is a new regulator of the Wnt 
signaling pathway or at least related to this pathway? 
The western blot of β-catenin upon TRIM71 overexpression and knockdown in our study 
showed the predictive result. TRIM71 induction causes β-catenin accumulation, while its 
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reduction decreased β-catenin, which was interestingly observed only in HepT1 and 
HUH6 cells, the two HB cell lines with CTNNB1 mutation. A recent genome-wide 
expression analysis revealed that certain genes were constantly upregulated in HB tumors: 
LIN28B, HMGA2, AFP and DLK1 [71]. The first two genes are linked to the Wnt signaling 
pathway and were uncovered up-regulated in HB tumor samples in our study as well. 
According to the literature [47, 50, 72, 73] and based on our new findings, we set up a 
regulatory network (Figure. 17). Let-7 is known as a tumor suppressor, and LIN28B, 
IGF2BP1, and HMGA2 are three downstream targets of it in cancer cells which have been 
proved working as oncogenes [73]. LIN28B, IGF2BP1, and HMGA2 can unsurprisingly 
induce cancer cell proliferation and tumor growth [74, 75] or even induce aggressive 
phenotypes. Then, a feedback were found that LIN28B represses let-7 via a zcchc11-
independent mechanism [41], while LIN28B expression is only enhanced by IGF2BP1 
substantially. Let-7-LIN28B-IGF2BP1 potentially become a triangle, that we can assume 
LIN28B itself overexpression may abolish let-7 synthesis and cause the IGF2BP1 
stimulation. Let-7 negatively regulates TRIM71 has been proven in several studies [76, 
77] and more importantly TRIM71 has been investigated to suppress both let-7 and 
LIN28B [50, 72]. It should be noted that TRIM71 is unusual in this total interactome 
considering its unique position. Moreover, TRIM71 has been proved as an oncogene in 
HCC [48], while during this study we found its role in HB is more diverse.   
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Figure. 17 The interplay of candidate genes and their functional role. Genes related to hepatic liver 
tumor formation are specifically listed in this functional network. let-7 is an inhibitor of LIN28B in the feedback 
mechanism. This inhibition of LIN28B can be accomplished by let-7 through activation of TRIM71, which 
targets LIN28B for ubiquitin-mediated proteasomal degradation. IGF2BP1 and HMGA2 are two targets of 
let-7 which have been investigated working as oncogenes. Besides, IGF2BP1 positively regulates LIN28B 
which forms a feedback triangle between let-7, LIN28B, IGF2BP1. Our study found β-catenin can result in 
TRIM71 accumulation. MYC is a Wnt target and among the most potent oncogenes associated with HCC 
development in mice [78]. The dashed line stands for hypothetical interactions from our study and the full 
lines are the proven interactions from the literature.  
 
TRIM71, LIN28B, HMGA2, and IGF2BP1 expression in HBs was tightly positively 
correlated with each other. Interestingly, these genes are all suppressed by let-7 
(Figure.17). LIN28B, a small RNA-binding protein, can promote proliferation and repress 
differentiation as a consistent idea with available data supporting, at least in part through 
repressing let-7 biogenesis [51]. And LIN28B has also been proven as a specific substrate 
of TRIM71, its oncogenic activity is repressed post-transcriptionally by TRIM71. According 
Discussion 
 
41 
to the result in our study, that TRIM71 inhibits cell proliferation only in HB could be due to 
its TRIM71-LIN28B mode of action. But the interplay loop is always more complex than 
other mechanisms, for instance, HMGA2 is a gene that is essential in some tumor 
malignancies for metastasis [79, 80], but appeared not to be functionally linked in this 
study. On the other side, LIN28B suppresses let-7, which then down-regulates TRIM71, 
while TRIM71 downregulates these two genes. This triple-negative feedback may be 
switched by several specific factors or signals that reinforces developmental steps. 
Certainly, in rare cases, this specific loop results in de-differentiation, proliferation or even 
other tumor formation. It seems that this switch may be responsible for HCC development 
where LIN28B displays heterochronic expression [81].  
The interplay of Wnt/β-catenin signaling and MYC in hepatoblastoma has been described 
to occur predominantly in immature tumors and to activate a distinct transcriptional 
program that correlates with tumor aggressiveness [82]. TRIM71 was proved a critical 
downstream effector for MYC enhancement of reprogramming [47]. As a target of MYC, 
it might be the reason why TRIM71 is up-regulated in hepatoblastoma. We hypothesize 
that TRIM71 causes β-catenin accumulation (Figure 17), although the analysis of the Wnt 
target genes in our study showed no significant upregulation of expression. It is still too 
early to perorate here due to the limitation of our data. Even though, TRIM71 is known as 
a critical factor that cooperates with AGO2 and binds to miRNA. This leads to post-
transcriptional repression of CDKN1A for promoting G1-S cell phase, but our study 
demonstrates TRIM71 inhibiting proliferation via LIN28B pathway overcomes its cell cycle 
enhancement and β-catenin tumor growth promotion activity in hepatoblastoma.  
 
2. TRIM71 might be an effector of stemness in pediatric hepatic tumor cells 
In this study, we performed several cell based assays trying to provide a comprehensive 
function of TRIM71 in childhood liver tumors. Scratch assay is a well-developed method 
for in vitro measuring cell migration. The results of our study suggest that aberrant TRIM71 
expression has no impact on migration in four cell lines. The absence of E-cadherin has 
been claimed to be related to nuclear accumulation of β-catenin in immature HBs [83], 
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and its interplay with growth-stimulating pathways evidenced in less differentiated cells. 
In addition, E-cadherin loss results in the induction of multiple transcription factors, as 
shown by gene expression analysis [84]. Absence of epithelial adhesion molecule E-
cadherin was thought to enable metastasis through disrupting intercellular contacts, which 
is an early step in metastatic dissemination [85]. Although E-cadherin detection in this 
study revealed its stronger signal in HepT1 and HUH6 cell lines, there was no difference 
upon TRIM71 overexpresses or knockdown. Moreover, TRIM71 mRNA expression in HB 
tumors showed no difference between tumors with or without metastasis and invasion. In 
conclusion, TRIM71 is no predictor of tumor metastasis.  
A small proportion of tumor cells named cancer stem cells (CSCs) are responsible to 
sustain tumor formation and growth, which are critical for cell renewal and cell growth. 
CSCs have recently been identified in many solid tumors, such as breast, liver, and colon 
[86, 87]. They harbor characteristic stem cell properties like self-renewal and 
differentiation. Results from this study showed that TRIM71 triggers the stimulation of 
colony formation capacity in both HBs and HCCs. This suggests that TRIM71 is able to 
induce cancer cell self-renewal capacity, which is in line with the finding that TRIM71 
accumulates β-catenin in HBs. Independend of the regulatory function of TRIM71, being 
either RNA binding or ubiquitin ligation, it is safe to predict that TRIM71 indirectly regulates 
stemness in HCC. TRIM71 is known to post-transcriptionally downregulate LIN28B, which 
has an important role in the promotion of stemness [88]. TRIM71 was proven to frequently 
associate with mRNA and immediately reduce their expression [89]. In 2014, TRIM71 was 
first time published as an upstream regulator of the LIN28B/let-7 pathway and negatively 
regulates miRNA let-7, which defined let-7 as a general inhibitor of self-renewal as well. If 
we rely on this pathway, isn’t it the opposite explanation of TRIM71 inducing CSC self-
renewal? So alternative mechanisms must be uncovered in this phenomenon. TRIM71 
was published to cooperate with Ago2 to repress expression of the cell cycle regulator 
CDKN1A, which negatively regulates G1-S transition. Thus, they demonstrated TRIM71 
is a factor responsible to promote rapid embryonic stem cell self-renewal. TRIM71 was 
identified not only to facilitate ESCs rapid proliferation, but also to balance stem cell self-
renewal and differentiation [61]. TRIM71 was reported to post-transcriptionally regulate 
the pro-differentiation transcription factor EGR1, which inhibits reprogramming [47]. 
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Notably, cell self-renewal was known to be supported by a shortening of G1 phase in 
human embryonic stem cells [90]. This means TRIM71 might contribute to promote 
reprogramming of the cell cycle, and finally, cancer cell self-renewal.   
 
3. Clinical value of TRIM71 in HB remains unclear 
Based on the results presented here the clinical relevance of TRIM71 in HB and HCC is 
not clear. The reason for this might be inferred from the multiple functions this protein has, 
which reach from its RNA binding activity to its ubiquitin ligase activity, and its multiple 
targets, containing several oncogenes and tumor-suppressors. Due to the limitation of our 
data available in this study, it is still not the time to conclude its precise role in hepatic liver 
tumors. Overall, our data clearly suggest that although TRIM71 promotes "stemness” in 
HB cell lines, it also inhibits cell proliferation. But the deep mechanism of TRIM71 remains 
unclear, that is worth to investigate in the future. 
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Outlook and perspectives 
P53 is a well-investigated tumor suppressor, and its expression level and activation are 
regulated by various TRIM proteins carrying E3 ubiquitin ligase activity, such as TRIM13, 
TRIM19, TRIM28 [91]. As a member of TRIM proteins, TRIM71 is one of the most 
important genes. Thus, its influence on p53 and further functional studies in hepatic 
childhood cancers should be discovered diligently. Moreover, better understanding of 
mechanisms of signaling pathways in regulating tumorigenicity, CSC self-renewal, 
proliferation, and differentiation always are critical for the development of effective 
anticancer therapies [92]. This study again provides evidence how important it is to 
integrate a gene into the pathway in research. TRIM71, involved in LIN28B/let-7 pathway, 
is a better entry point in the study of pediatric liver tumors. 
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Summary 
The TRIM71 (Tripartite Motif Containing 71) gene encodes the E3 ubiquitin-protein ligase 
that is able to hamper key factors through its ubiquitinylation and miRNA activities, thereby 
regulating growth and maintenance of embryonic stem cells. Moreover, it has been proven 
to be involved in many essential signaling pathways. TRIM71 was identified as a novel 
oncogenic protein in human liver cancer and as a strong predictor of poor prognosis. 
However, its role in pediatric liver tumors remains unknown. 
In this study, we aimed to identify the impact of TRIM71 in liver tumor behavior, to explore 
its clinical relevance for varying outcomes of childhood hepatoblastoma patients, to 
describe the regulatory network of candidate genes and to integrate it into a signaling 
pathway. We therefore made use of patient samples and four different liver tumor cell 
lines (derived from two hepatoblastomas and two hepatocellular carcinomas), in which 
expression analyses and TRIM71-modulating gain- and loss-of-function experiments were 
performed, respectively. 
TRIM71 is significantly overexpressed in 31 hepatoblastoma tumor compared to normal 
liver samples. TRIM71 induction inhibits cell proliferation, while its reduction stimulates 
cell proliferation, which is only observed in the ß-catenin mutated hepatoblastoma cells. 
However, no impacts could be found in apoptosis and migration due to TRIM71 up or 
down-regulation. Clonogenic assays identified the capacity of TRIM71 to raise self-
renewal in hepatoblastoma and hepatocellular carcinoma cells. Association analyses 
show that TRIM71 overexpression is a general phenomenon in hepatoblastoma, 
irrespective of their clinical characteristics. However, TRIM71 overexpression more likely 
appeared in tumors with ß-catenin mutations. Besides, TRIM71 overexpression drives β-
catenin accumulation in hepatoblastoma cells.  
In conclusion, we found that TRIM71 is frequently overexpressed in pediatric liver tumors, 
and that it negatively regulates cell proliferation, while it positively regulates cancer cell 
self-renewal. This might be triggered at least in part by the accumulation of mutant ß-
catenin, but its precise role in these molecular mechanisms has to be further investigated  
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Zusammenfassung 
Das Gen TRIM71 (Tripatite Motf Containing 71) kodiert eine E3 Ubiquitinligase, welche in 
einer Vielzahl essentieller zellulärer Signalwege involviert ist. Es hat sowohl durch die 
Ubiquitinylierung von Proteinen als auch durch Kooperation mit miRNAs eine wichtige 
Rolle für das Wachstum und den Erhalt embryonaler Stammzellen. Kürzlich konnte 
TRIM71 als onkogenes Protein in menschlichen Lebertumorzellen identifiziert werden und 
korreliert hier mit einem schlechteren Outcome. Ob TRIM71 auch bei der Entstehung 
pädiatrischer Lebertumoren involviert ist, ist bisher unbekannt. 
Ziel dieser Studie war es, den Einfluss von TRIM71 auf die Entwicklung pädiatrischer 
Lebertumoren und seine mögliche klinische Relevanz für das unterschiedliche Outcome 
von Patienten mit Hepatoblastom  zu erkunden. Weiterhin sollten verschiedene 
potentielle Zielgene identifiziert und TRIM71 dadurch in einen Signalweg intergiert werden. 
Dafür führten wir Expressionsanalysen an Patientenproben, sowie Experimente nach 
Überexpression oder Knockdown von TRIM71 in vier verschiedenen Lebertumorzelllinien 
durch (zwei Hepatoblastom- und zwei Hepatozelluläres Karzinom Zelllinien). 
Es zeigte sich, dass TRIM71 in den 31 getesteten Hepatoblastom-Patientenproben 
signifikant überexprimiert ist. Die Induktion von TRIM71 in den Zelllinien inhibiert ihre 
Proliferation, während verminderte Expression zu einer Wachstumsstimulation führte. 
Dies konnte jedoch nur in den Zelllinien gezeigt werden, die eine Mutation von ß-catenin 
vorweisen. Hoch- oder Runterregulation von TRIM71 hatte keinen Effekt auf Apoptose 
und das Migationsverhalten der Zellen. In klonogenen Assays konnte beobachtet werden, 
dass TRIM71 einen Einfluss auf die Fähigkeit zur Selbsterneuerung der Hepatoblastom- 
und Hepatozellüräres Karzinom-Zellen hat. Bei der Assoziation mit klinischen Parametern 
der getesteten Patientenproben zeigte sich, dass die Überexpression von TRIM71 ein 
generelles Phänomen des Hepatoblastoms ist, welches nicht mit bestimmten klinischen 
Parametern korreliert. Es zeigte sich jedoch, dass eine Überexpression häufiger bei 
Tumoren mit einer ß-catenin Mutation auftritt. Weiterhin führt die Überexpression zu einer 
Akkumulation von ß-catenin in Hepatoblastom-Zellen. 
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Zusammenfassend zeigte sich, dass TRIM71 häufig in pädiatrischen Lebertumoren 
überexprimiert ist. Es hemmt die die Zellproliferation, verstärkt jedoch die Fähigkeit zur 
Selbsterneuerung von Tumorzellen. Dies könnte möglicherweise zum Teil durch die 
Akkumulation von mutiertem ß-catenin im Zellkern beeinflusst sein, sein genauer Einfluss 
auf die molekularen Mechanismen ist jedoch nicht abschließend geklärt. 
 
 
References 
 
48 
References 
1. Allan, B.J., et al., Predictors of survival and incidence of hepatoblastoma in the paediatric population. 
HPB (Oxford), 2013. 15(10): p. 741-6. 
2. Sumazin, P., et al., Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic 
subgroups. Hepatology, 2017. 65(1): p. 104-121. 
3. Zimmermann, A., Hepatoblastoma and the Hepatoblastoma Family of Tumors, in Tumors and Tumor-
Like Lesions of the Hepatobiliary Tract: General and Surgical Pathology, A. Zimmermann, Editor. 2017, 
Springer International Publishing: Cham. p. 357-393. 
4. Spector, L.G. and J. Birch, The epidemiology of hepatoblastoma. Pediatr Blood Cancer, 2012. 59(5): p. 
776-9. 
5. Schmid, I. and D. von Schweinitz, Pediatric hepatocellular carcinoma: challenges and solutions. J 
Hepatocell Carcinoma, 2017. 4: p. 15-21. 
6. Wu, J.F., et al., Prognostic roles of pathology markers immunoexpression and clinical parameters in 
Hepatoblastoma. J Biomed Sci, 2017. 24(1): p. 62. 
7. Busweiler, L.A., et al., Surgical treatment of childhood hepatoblastoma in the Netherlands (1990-
2013). Pediatr Surg Int, 2017. 33(1): p. 23-31. 
8. Czauderna, P., Is it worth completely resecting hepatoblastoma at diagnosis? Lancet Oncol, 2019. 
20(5): p. 614-615. 
9. Roebuck, D.J., et al., 2005 PRETEXT: a revised staging system for primary malignant liver tumours of 
childhood developed by the SIOPEL group. Pediatr Radiol, 2007. 37(2): p. 123-32; quiz 249-50. 
10. Roebuck, D.J., Assessment of malignant liver tumors in children. Cancer Imaging, 2009. 9 Spec No 
A(Special issue A): p. S98-S103. 
11. Rowland, J.M., Hepatoblastoma: Assessment of criteria for histologic classification. Medical and 
Pediatric Oncology, 2002. 39(5): p. 478-483. 
12. Weber, R.G., et al., Characterization of genomic alterations in hepatoblastomas: a role for gains on 
chromosomes 8q and 20 as predictors of poor outcome. The American journal of pathology, 2000. 157(2): 
p. 571-578. 
13. Cairo, S., et al., Hepatic stem-like phenotype and interplay of Wnt/β-catenin and Myc signaling in 
aggressive childhood liver cancer. Cancer cell, 2008. 14(6): p. 471-484. 
14. López-Terrada, D., et al., Histologic subtypes of hepatoblastoma are characterized by differential 
canonical Wnt and Notch pathway activation in DLK+ precursors. Human pathology, 2009. 40(6): p. 783-
794. 
15. Gröbner, S.N., et al., The landscape of genomic alterations across childhood cancers. Nature, 2018. 
555: p. 321. 
References 
 
49 
16. Jeng, Y.-M., et al., Somatic mutations of β-catenin play a crucial role in the tumorigenesis of sporadic 
hepatoblastoma. Cancer letters, 2000. 152(1): p. 45-51. 
17. Taniguchi, K., et al., Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas 
and hepatoblastomas. Oncogene, 2002. 21(31): p. 4863. 
18. Yang, J., et al., Beta‐catenin signaling in murine liver zonation and regeneration: A Wnt‐Wnt 
situation! Hepatology, 2014. 60(3): p. 964-976. 
19. Monga, S.P., et al., Changes in WNT/β-catenin pathway during regulated growth in rat liver 
regeneration. Hepatology, 2001. 33(5): p. 1098-1109. 
20. Uematsu, K., et al., Activation of the Wnt pathway in non small cell lung cancer: evidence of 
dishevelled overexpression. Oncogene, 2003. 22(46): p. 7218. 
21. Bienz, M. and H. Clevers, Linking colorectal cancer to Wnt signaling. Cell, 2000. 103(2): p. 311-320. 
22. Howe, L.R. and A.M. Brown, Wnt signaling and breast cancer. Cancer biology & therapy, 2004. 3(1): p. 
36-41. 
23. Takigawa, Y. and A. Brown, Wnt signaling in liver cancer. Current drug targets, 2008. 9(11): p. 1013-
1024. 
24. Price, M.A., CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. 
Genes Dev, 2006. 20(4): p. 399-410. 
25. Wong, H.-C., et al., Direct Binding of the PDZ Domain of Dishevelled to a Conserved Internal Sequence 
in the C-Terminal Region of Frizzled. Molecular Cell, 2003. 12(5): p. 1251-1260. 
26. Tolwinski, N.S., et al., Wg/Wnt Signal Can Be Transmitted through Arrow/LRP5,6 and Axin 
Independently of Zw3/Gsk3β Activity. Developmental Cell, 2003. 4(3): p. 407-418. 
27. Kramps, T., et al., Wnt/Wingless Signaling Requires BCL9/Legless-Mediated Recruitment of Pygopus 
to the Nuclear β-Catenin-TCF Complex. Cell, 2002. 109(1): p. 47-60. 
28. Chamorro, M.N., et al., FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is 
implicated in cancer and development. EMBO J, 2005. 24(1): p. 73-84. 
29. Yang, K., et al., The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: 
implications in targeted cancer therapies. Laboratory Investigation, 2015. 96: p. 116. 
30. Li, X.Y., et al., Enhanced expression of circular RNA hsa_circ_000984 promotes cells proliferation and 
metastasis in non-small cell lung cancer by modulating Wnt/beta-catenin pathway. Eur Rev Med 
Pharmacol Sci, 2019. 23(8): p. 3366-3374. 
31. Jin, Y.D., et al., Hsa_circ_0005075 predicts a poor prognosis and acts as an oncogene in colorectal 
cancer via activating Wnt/beta-catenin pathway. Eur Rev Med Pharmacol Sci, 2019. 23(8): p. 3311-3319. 
32. Mo, D., et al., A tRNA fragment, 5'-tiRNA(Val), suppresses the Wnt/beta-Catenin signaling pathway by 
targeting FZD3 in breast cancer. Cancer Lett, 2019. 
33. Polakis, P., Wnt signaling and cancer. Genes Dev, 2000. 14(15): p. 1837-51. 
References 
 
50 
34. Yang, J., et al., beta-catenin signaling in murine liver zonation and regeneration: a Wnt-Wnt situation! 
Hepatology, 2014. 60(3): p. 964-76. 
35. Monga, S.P., et al., Changes in WNT/beta-catenin pathway during regulated growth in rat liver 
regeneration. Hepatology, 2001. 33(5): p. 1098-109. 
36. Yang, K., et al., The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: 
implications in targeted cancer therapies. Laboratory investigation, 2016. 96(2): p. 116. 
37. Ota, T., et al., Complete sequencing and characterization of 21,243 full-length human cDNAs. Nature 
genetics, 2004. 36(1): p. 40. 
38. Beachy, S.H., et al., Enforced expression of Lin28b leads to impaired T-cell development, release of 
inflammatory cytokines, and peripheral T-cell lymphoma. Blood, 2012. 120(5): p. 1048-1059. 
39. Nguyen, Liem H., et al., Lin28b Is Sufficient to Drive Liver Cancer and Necessary for Its Maintenance 
in Murine Models. Cancer Cell, 2014. 26(2): p. 248-261. 
40. Thornton, J.E. and R.I. Gregory, How does Lin28 let-7 control development and disease? Trends in Cell 
Biology, 2012. 22(9): p. 474-482. 
41. Piskounova, E., et al., Lin28A and Lin28B Inhibit let-7 MicroRNA Biogenesis by Distinct Mechanisms. 
Cell, 2011. 147(5): p. 1066-1079. 
42. Balzeau, J., et al., The LIN28/let-7 Pathway in Cancer. Frontiers in Genetics, 2017. 8(31). 
43. Roush, S. and F.J. Slack, The let-7 family of microRNAs. Trends in cell biology, 2008. 18(10): p. 505-
516. 
44. Loedige, I., et al., The mammalian TRIM-NHL protein TRIM71/LIN-41 is a repressor of mRNA function. 
Nucleic Acids Res, 2013. 41(1): p. 518-32. 
45. Tocchini, C. and R. Ciosk, TRIM-NHL proteins in development and disease. Seminars in Cell & 
Developmental Biology, 2015. 47-48: p. 52-59. 
46. Treiber, T., et al., A Compendium of RNA-Binding Proteins that Regulate MicroRNA Biogenesis. Mol 
Cell, 2017. 66(2): p. 270-284 e13. 
47. Worringer, K.A., et al., The let-7/LIN-41 pathway regulates reprogramming to human induced 
pluripotent stem cells by controlling expression of prodifferentiation genes. Cell stem cell, 2014. 14(1): p. 
40-52. 
48. Chen, Y.L., et al., The stem cell E3‐ ligase Lin‐41 promotes liver cancer progression through 
inhibition of microRNA‐mediated gene silencing. The Journal of pathology, 2013. 229(3): p. 486-496. 
49. McDaniel, K., et al., Lin28 and let-7: roles and regulation in liver diseases. American Journal of 
Physiology-Gastrointestinal and Liver Physiology, 2016. 310(10): p. G757-G765. 
50. Yin, J., et al., TRIM71 suppresses tumorigenesis via modulation of Lin28B-let-7-HMGA2 signaling. 
Oncotarget, 2016. 7(48): p. 79854. 
References 
 
51 
51. Rybak, A., et al., A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during 
neural stem-cell commitment. Nature cell biology, 2008. 10(8): p. 987. 
52. Lee, S.H., et al., The ubiquitin ligase human TRIM71 regulates let-7 microRNA biogenesis via 
modulation of Lin28B protein. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 2014. 
1839(5): p. 374-386. 
53. Pietsch, T., et al., Characterization of the continuous cell line HepT1 derived from a human 
hepatoblastoma. Lab Invest, 1996. 74(4): p. 809-18. 
54. Kim, J.H. and J.D. Richter, Opposing Polymerase-Deadenylase Activities Regulate Cytoplasmic 
Polyadenylation. Molecular Cell, 2006. 24(2): p. 173-183. 
55. Pfaffl, M.W., A new mathematical model for relative quantification in real-time RT–PCR. Nucleic acids 
research, 2001. 29(9): p. e45-e45. 
56. Nakabayashi, H., et al., Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term 
culture with chemically defined medium. Gan, 1984. 75(2): p. 151-8. 
57. Nakabayashi, H., et al., Growth of human hepatoma cells lines with differentiated functions in 
chemically defined medium. Cancer Res, 1982. 42(9): p. 3858-63. 
58. Saint-Auret, G., et al., Characterization of the transcriptional signature of C/EBPbeta isoforms (LAP/LIP) 
in Hep3B cells: implication of LIP in pro-survival functions. J Hepatol, 2011. 54(6): p. 1185-94. 
59. Doi, I., Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gan, 
1976. 67(1): p. 1-10. 
60. Oishi, K., et al., Efficient transfection of sendai virus vector to mouse pancreatic stem cells in the 
floating state. Cell Transplant, 2010. 19(6): p. 893-900. 
61. Chang, H.-M., et al., Trim71 cooperates with microRNAs to repress Cdkn1a expression and promote 
embryonic stem cell proliferation. Nature Communications, 2012. 3: p. 923. 
62. Cairo, S., et al., Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in 
aggressive childhood liver cancer. Cancer Cell, 2008. 14(6): p. 471-84. 
63. Yang, W., et al., Wnt/β-catenin signaling contributes to activation of normal and tumorigenic liver 
progenitor cells. Cancer research, 2008. 68(11): p. 4287-4295. 
64. Evan, G.I. and K.H. Vousden, Proliferation, cell cycle and apoptosis in cancer. nature, 2001. 411(6835): 
p. 342. 
65. Hatakeyama, S., TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis. Trends in 
Biochemical Sciences, 2017. 42(4): p. 297-311. 
66. Schwamborn, J.C., E. Berezikov, and J.A. Knoblich, The TRIM-NHL protein TRIM32 activates microRNAs 
and prevents self-renewal in mouse neural progenitors. Cell, 2009. 136(5): p. 913-925. 
67. Raheja, R., et al., The ability of TRIM3 to induce growth arrest depends on RING-dependent E3 ligase 
activity. Biochemical Journal, 2014. 458(3): p. 537-545. 
References 
 
52 
68. Ferreira, A., et al., Mei-P26 mediates tissue-specific responses to the Brat tumor suppressor and the 
dMyc proto-oncogene in Drosophila. Genetics, 2014. 198(1): p. 249-258. 
69. Heikel, G., N.R. Choudhury, and G. Michlewski, The role of Trim25 in development, disease and RNA 
metabolism. Biochemical Society Transactions, 2016. 44(4): p. 1045-1050. 
70. Urano, T., et al., Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth. Nature, 2002. 
417(6891): p. 871. 
71. Sumazin, P., et al., Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic 
subgroups. Hepatology, 2017. 65(1): p. 104-121. 
72. Treiber, T., et al., A compendium of RNA-binding proteins that regulate microRNA biogenesis. 
Molecular cell, 2017. 66(2): p. 270-284. e13. 
73. Busch, B., et al., The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-
suppressive actions of the let-7 family. Nucleic acids research, 2016. 44(8): p. 3845-3864. 
74. Malek, A., et al., HMGA2 gene is a promising target for ovarian cancer silencing therapy. International 
Journal of Cancer, 2008. 123(2): p. 348-356. 
75. Stöhr, N., et al., IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling. Genes & 
development, 2012. 26(2): p. 176-189. 
76. Lin, Y.-C., et al., Human TRIM71 and its nematode homologue are targets of let-7 microRNA and its 
zebrafish orthologue is essential for development. Molecular biology and evolution, 2007. 24(11): p. 2525-
2534. 
77. Rybak, A., et al., The let-7 target gene mouse lin-41 is a stem cell specific E3 ubiquitin ligase for the 
miRNA pathway protein Ago2. Nature cell biology, 2009. 11(12): p. 1411. 
78. Vita, M. and M. Henriksson, The Myc oncoprotein as a therapeutic target for human cancer. Seminars 
in Cancer Biology, 2006. 16(4): p. 318-330. 
79. Zhao, X.-P., et al., Overexpression of HMGA2 promotes tongue cancer metastasis through EMT 
pathway. Journal of translational medicine, 2016. 14(1): p. 26. 
80. Dong, J., et al., HMGA2–FOXL2 axis regulates metastases and epithelial-to-mesenchymal transition of 
chemoresistant gastric cancer. Clinical Cancer Research, 2017. 23(13): p. 3461-3473. 
81. Guo, Y., et al., Identification and characterization of lin-28 homolog B (LIN28B) in human 
hepatocellular carcinoma. Gene, 2006. 384: p. 51-61. 
82. Cairo, S., et al., Hepatic Stem-like Phenotype and Interplay of Wnt/β-Catenin and Myc Signaling in 
Aggressive Childhood Liver Cancer. Cancer Cell, 2008. 14(6): p. 471-484. 
83. Dianati, E., et al., Connexins, E-cadherin, Claudin-7 and β-catenin transiently form junctional nexuses 
during the post-natal mammary gland development. Developmental biology, 2016. 416(1): p. 52-68. 
84. Onder, T.T., et al., Loss of E-cadherin promotes metastasis via multiple downstream transcriptional 
pathways. Cancer research, 2008. 68(10): p. 3645-3654. 
References 
 
53 
85. Onder, T.T., et al., Loss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional 
Pathways. Cancer Research, 2008. 68(10): p. 3645. 
86. Haraguchi, N., et al., CD13 is a therapeutic target in human liver cancer stem cells. The Journal of 
clinical investigation, 2010. 120(9): p. 3326-3339. 
87. Visvader, J.E. and G.J. Lindeman, Cancer stem cells: current status and evolving complexities. Cell stem 
cell, 2012. 10(6): p. 717-728. 
88. Chen, C., et al., Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment 
to suppress cancer stemness and metastasis. Oncogene, 2019: p. 1. 
89. Kwon, S.C., et al., The RNA-binding protein repertoire of embryonic stem cells. Nature Structural 
&Amp; Molecular Biology, 2013. 20: p. 1122. 
90. Becker, K.A., et al., Self-renewal of human embryonic stem cells is supported by a shortened G1 cell 
cycle phase. Journal of Cellular Physiology, 2006. 209(3): p. 883-893. 
91. Hock, A. and K.H. Vousden, Regulation of the p53 pathway by ubiquitin and related proteins. The 
international journal of biochemistry & cell biology, 2010. 42(10): p. 1618-1621. 
92. Noh, K.H., et al., Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an 
immune-resistant and stem-like phenotype. Cancer research, 2012. 72(7): p. 1717-1727. 
Abbreviations 
 
54 
Abbreviations 
HB                        Hepatoblastoma  
HCC                      Hepatocellular carcinoma 
RPMI                     Roswell Park Memorial Institute Medium 
PS                        Penicillin-Streptomycin 
DPBS                     Dulbecco’s Phosphate-Buffered Saline 
FCS                       Fetal Calf Serum 
dNTPs                     deoxynucleotides triphosphate  
DMEM                     Dulbecco`s Medium 
EDTA                      Ethylenediaminetetraacetic acid 
PBS-T                     Phosphate buffered saline and 0.1% Teen-20 
β-actin                     Beta actin 
β-catenin                   Beta catenin 
PCR                       Polymerase chain reaction 
RT-PCR                    Real time-polymerase chain reaction 
PRETEXT                  Pretreatment extent of tumor 
TRIM71                    Tripartite Motif Containing 71 
CSC                       Cancer stem cell 
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